Q32 Bio (QTTB) Director Mark T. Iwicki Receives Award of 10,826 Options

What Happened
Mark T. Iwicki, a director of Q32 Bio Inc. (QTTB), received an award of derivative securities covering 10,826 shares on June 12, 2026. The Form 4 records the transaction as an award/acquisition with a transaction price of $0.00 (no cash paid at grant). The filing on July 21, 2026 is an amendment to the original Form 4 to correct the number of options awarded.

Key Details

• Transaction date: June 12, 2026; Form 4 amendment filed July 21, 2026 (original Form 4 filed June 16, 2026).
• Transaction type: Grant/award of derivative securities (options) for 10,826 shares; transaction price listed as $0.00.
• Vesting: The shares underlying the option vest in full upon the earlier of (i) June 12, 2027 or (ii) the issuer’s next annual meeting of stockholders, subject to the reporting person’s continued service.
• Shares owned after transaction: Not specified in the provided excerpt of the filing.
• Amendment purpose: Correct the number of options awarded on June 12, 2026 (per footnote).

Context

• This is a grant of options (a derivative award), not a cash purchase or sale of stock. No immediate sale or cashless exercise is reported.
• Such grants are typically compensation-related and subject to vesting and service conditions; they do not by themselves indicate the director bought or sold existing shares.
• The amendment corrects the reported award size; the original Form 4 filing appears to have been timely (filed June 16, 2026, within the typical Form 4 reporting window).